The Board of Infinity Pharmaceuticals, Inc. approved the termination, without cause, of the employment of Adelene Perkins as Chief Executive Officer of the Company, effective September 1, 2023. Ms. Perkins will remain the chair of the Board. On August 29, 2023, the Board approved the appointment, effective as of September 1, 2023, of Seth Tasker, J.D., 45, as Chief Executive Officer of the Company.

Mr. Tasker has served as the Company?s Senior Vice President, Chief Business Officer since January 2020. Previously, Mr. Tasker served as the Company?s Vice President, General Counsel from July 2016 to January 2020. Mr. Tasker has more than 17 years of experience in the pharmaceutical industry and brings expertise in corporate finance and partnering transactions, corporate governance, securities, compliance, employment law and other legal and operational issues relevant to developing new medicines in both the private and public company setting.

Prior to joining the Company in 2008, Mr. Tasker served as associate counsel at Surface Logix, Inc., a privately held biotechnology company focused on developing improved drug therapies addressing Type 2 diabetes, cardiovascular health and oncology. Mr. Tasker received a J.D. and M.B. A from Suffolk University and a B.S. in microbiology from the University of Vermont. Mr. Tasker has no family relationships with any of the Company?s directors or executive officers.